Preliminary Amendment – Crothers et al.

Page 3

Amendments to the Claims:

Before claim 1 on amended page 33 insert -- We claim:--

This listing of claims will replace all prior versions, and listings, of claims in the

application:

Listing of Claims:

(Currently Amended) An encapsulated product comprising[:]

a plurality of micro-capsules formed from a plurality of micro-organisms and having a

lipophilic active encapsulated and passively retained within said micro-capsules, said lipophilic

active not being a natural constituent of said micro-organisms, each of said micro-capsules

having:

(a) an at least substantially intact cell wall; and

(b) an intact cell membrane;

wherein said micro-capsules are formulated to target delivery of said micro-capsules and said

lipophilic active to <u>aat least one</u> desired at least one mucous membrane.

2. (Original) An encapsulated product according to claim 1, wherein said micro-capsules

are formulated as one of the group consisting of: syrup, sachet, chewable, chewing gum,

orodispersible, dispersible effervescent, dispersible tablet, compressed buccal tablet, compressed

sublingual tablet, chewable tablet, melt-in-the-mouth, lozenge, paste, suspension, powder, gel,

tablet, compressed sweet, boiled sweet, cream, suppository, snuff spray, aerosol, pessary, and

ointment.

Preliminary Amendment – Crothers et al. Page 4

- 3. (Currently Amended) An encapsulated product according to claim 1, wherein said microcapsules are formulated within one of a one-part gelatin capsule, a-or two-part gelatin capsule, and or an enteric coating.
- 4. (Currently Amended) A method of manufacture manufacturing of an encapsulated product, wherein said encapsulated product comprises a plurality of micro-capsules formed from a plurality of micro-organisms, comprising the step of:
- (i) contacting said micro-organisms with a lipophilic active to encapsulate said lipophilic active within said micro-organisms[;], said lipophilic active being encapsulated and passively retained within said micro-capsules, said lipophilic active not being a natural constituent of said micro-organism, said micro-capsules having:
 - (a) an at least substantially intact cell wall[;], and
 - (b) an intact cell membrane [;;] and further comprising the step of:
- (ii) formulating said micro-capsules to target delivery of said micro-capsules and said lipophilic active to <u>aat least one</u> desired <u>at least one</u> biological membrane.

Preliminary Amendment – Crothers et al. Page 5

- 5. (Currently Amended) A method of manufacture manufacturing of an encapsulated product according to claim 4, additionally comprising[,] prior to said encapsulation step, an encapsulation step, and enca
- 6. (Currently Amended) A method of manufacture manufacturing of an encapsulated product according to either one of claims 4 and 5, additionally comprising 1 after said encapsulation step or said additional treatment step, performing a conditioning step, wherein in which said micro-capsules are incubated in a dry environment between 15-50 degrees C.
- 7. (Currently Amended) A method of manufacture-manufacturing of an encapsulated product according to any one of claims 4[-6], wherein said encapsulation contacting step comprises contacting, for each of said micro-organisms, saida micro-organism with a lipophilic active in liquid form, said lipophilic active being capable of diffusing into saida cell wall of said micro-organism without causing total lysation thereof, the treatment-contacting step being carried out in the absence of a lipid extending substance as a solvent or microdispersant for the active and in the absence of a plasmolyser, whereby the active is absorbed by the micro-organism by diffusion across said cell wall and is retained passively within said micro-organism.

Preliminary Amendment – Crothers et al. Page 6

8. (Currently Amended) An encapsulated product according to any one of claims 1, 3 or a

method of manufacture of an encapsulated product according to any one of claims 4-7 wherein

each of said micro-organism[s] is selected from the group consisting of: fungus, bacterium, alga

and protozoa.

9. (Currently Amended) An encapsulated product or a method of manufacture of an

encapsulated product according to claim 8[.] wherein said micro-organism is a yeast selected

from the taxonomic order Endornycetales.

10. (Currently Amended) A method of treatment treating of a patient comprising

administering to said patient a medicament comprising the product of any one of claims 1-3, 8 or

9.

11. (New) A method of manufacturing an encapsulated product according to claim 4,

wherein each of said micro-organisms is selected from the group consisting of: fungus,

bacterium, alga and protozoa.

12. (New) A method of manufacturing an encapsulated product according to claim 11,

wherein said micro-organism is a yeast selected from the taxonomic order Endornycetales.